Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-003 for moderate-to-severe seasonal allergic rhinitis
CTR20231145Phase 2Completed
- Sponsor
- Tianchen Biopharmaceuticals
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LP-003 in seasonal allergic rhinitis (SAR), sponsored by Tianchen Biopharmaceuticals. Started Apr 2023; status: completed.
02
Drugs
LP-003
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20231145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231145.